IN8bio, Inc. (NASDAQ:INAB) Short Interest Up 768.0% in February

IN8bio, Inc. (NASDAQ:INAB) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 3,760,000 shares, an increase of 768.0% from the January 31st total of 433,200 shares. Approximately 6.5% of the shares of the company are short sold. Based on an average daily volume of 4,930,000 shares, the short-interest ratio is presently 0.8 days.

IN8bio Stock Down 4.9 %

IN8bio stock opened at $0.25 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84. IN8bio has a fifty-two week low of $0.22 and a fifty-two week high of $1.74. The company has a market cap of $18.37 million, a PE ratio of -0.34 and a beta of 0.05. The business’s 50-day simple moving average is $0.28 and its two-hundred day simple moving average is $0.33.

Hedge Funds Weigh In On IN8bio

Several hedge funds and other institutional investors have recently bought and sold shares of INAB. BIOS Capital Management LP acquired a new position in IN8bio during the fourth quarter valued at $2,212,000. Alyeska Investment Group L.P. raised its stake in shares of IN8bio by 1,064.5% during the 4th quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock valued at $1,302,000 after buying an additional 4,628,482 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of IN8bio by 296.7% in the 4th quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock valued at $30,000 after buying an additional 86,696 shares during the period. Geode Capital Management LLC boosted its stake in shares of IN8bio by 56.5% in the fourth quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock worth $133,000 after buying an additional 185,919 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new stake in IN8bio during the fourth quarter worth about $1,465,000. Institutional investors and hedge funds own 92.05% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of IN8bio in a report on Wednesday, February 12th.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.